This study presents a BRET biosensor that measures how anticancer drugs cooperatively engage PRMT5 complexes in cells, revealing how cellular metabolites such as SAM and MTA enhance drug action and enable precision therapies for MTAP-deleted tumors.
- Elisabeth M. Rothweiler
- Ani Michaud
- Kilian V. M. Huber